Neurotensin (NT)
Neurotensin is a 13-amino acid neuropeptide with endogenous antipsychotic-like properties, mediating hypothermia, antinociception, and dopamine modulation through NTS1 and NTS2 receptors. It is investigated as a basis for novel antipsychotic agents targeting schizophrenia without extrapyramidal side effects.
Neurotensin (NT) is a 13-amino acid neuropeptide first isolated from bovine hypothalamus in 1973 by Carraway and Leeman. It functions as both a neurotransmitter in the central nervous system and a paracrine/endocrine hormone in the gut.
Overview
Neurotensin is distributed throughout the central nervous system, with highest concentrations in the hypothalamus, amygdala, nucleus accumbens, ventral tegmental area (VTA), and substantia nigra — regions intimately associated with dopamine signaling, reward, and thermoregulation. In the periphery, neurotensin is produced by N-cells in the ileal mucosa, where it is released postprandially (particularly in response to fat) and facilitates lipid absorption, GI motility, and pancreatic/biliary secretion.
The central neurotensin system has attracted sustained pharmacological interest because of its antipsychotic-like profile. Central NT administration in rodents produces effects remarkably similar to classical antipsychotic drugs — reduced locomotor activity, hypothermia, catalepsy, blockade of amphetamine-induced hyperlocomotion, and increased dopamine turnover — but through direct neuropeptide receptor mechanisms rather than dopamine receptor blockade. This has motivated the development of NT receptor agonists as potential antipsychotic agents that might avoid the extrapyramidal side effects and metabolic consequences of conventional neuroleptics.
Mechanism of Action
Neurotensin signals through three receptor types:
- NTS1 (NTSR1): A Gq/11-coupled GPCR that activates PLC → IP₃/DAG → Ca²⁺ release. This is the primary receptor mediating NT's hypothermic, analgesic, and antipsychotic-like effects. NTS1 is expressed in the VTA, substantia nigra, nucleus accumbens, prefrontal cortex, and amygdala. NTS1 activation modulates mesolimbic and mesocortical dopamine transmission without directly blocking dopamine receptors Vincent et al. (1999).
- NTS2 (NTSR2): A GPCR with lower affinity for NT that primarily mediates analgesic effects, particularly in the spinal cord and periaqueductal gray. NTS2 couples to both Gq and Gi, and NTS2-selective agonists produce analgesia without the hypothermia associated with NTS1 activation Sarret et al. (2003).
- NTS3 (Sortilin): A single-transmembrane sorting receptor (not a GPCR) involved in NT trafficking, clearance, and signaling modulation. Sortilin mediates NT internalization and intracellular sorting, influencing NT bioavailability and signaling duration.
- Dopamine interaction: NT released in the VTA and nucleus accumbens modulates dopamine neuron firing, dopamine release, and dopamine receptor sensitivity. NT enhances dopamine transmission in the prefrontal cortex (potentially improving negative symptoms) while attenuating excessive mesolimbic dopamine (potentially reducing positive symptoms) — a profile matching the ideal antipsychotic Binder et al. (2001).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Dopamine Modulation
Neurotensin neurons form dense synaptic connections with dopamine neurons in the VTA and substantia nigra. NT release in the VTA increases dopamine neuron firing rate and dopamine release in the prefrontal cortex (mesocortical pathway), while simultaneously modulating mesolimbic dopamine transmission to the nucleus accumbens. This pathway-selective modulation is pharmacologically significant: enhancing mesocortical dopamine could address negative symptoms and cognitive deficits in schizophrenia, while attenuating mesolimbic dopamine could reduce positive symptoms — without the broad dopamine blockade that causes extrapyramidal symptoms Binder et al. (2001).
Hypothermia
NT produces potent, dose-dependent hypothermia when administered centrally, reducing core body temperature by 2–6°C in rodents. This effect is mediated primarily by NTS1 receptors in the preoptic/anterior hypothalamic area and is one of the most robust and reproducible effects of central NT administration. NT-induced hypothermia has been explored for neuroprotection in stroke and traumatic brain injury, where controlled hypothermia reduces infarct size and improves neurological outcomes Bhagwandin et al. (2022).
Antinociception
NT produces potent non-opioid analgesia that is not reversed by naloxone, distinguishing it from endorphin-mediated pain modulation. NTS1-mediated analgesia involves supraspinal circuits (periaqueductal gray, rostral ventromedial medulla), while NTS2-mediated analgesia operates at both supraspinal and spinal levels Sarret et al. (2003). NT analgesic potency is comparable to morphine in some models, and tolerance to NT analgesia develops more slowly than to opioids. NTS2-selective agonists are of particular interest as they produce analgesia without the hypothermia and hypotension associated with NTS1 activation, offering a potential pathway to non-opioid analgesics.
Fat Absorption and Metabolism
In the periphery, neurotensin is released from ileal N-cells primarily in response to luminal fat. NT facilitates fat absorption by stimulating pancreatic lipase secretion, biliary flow, and intestinal motility. Elevated fasting neurotensin levels (pro-NT, the stable precursor fragment) have been associated with increased risk of obesity, diabetes, cardiovascular disease, and breast cancer in large epidemiological studies Melander et al. (2012). NT knockout mice are protected from high-fat diet-induced obesity, suggesting NT promotes fat storage and metabolic dysfunction under conditions of caloric excess.
NT Receptor Agonists for Schizophrenia
The antipsychotic-like profile of neurotensin has driven development of NTS1 receptor agonists as novel antipsychotic agents. Key challenges include poor blood-brain barrier penetration of native NT, rapid enzymatic degradation, and NTS1-associated hypothermia and hypotension. Brain-penetrant NT(8-13) analogs — including PD149163 and NTRC-844 — show antipsychotic-like efficacy in preclinical models with reduced metabolic side effects compared to second-generation antipsychotics Ferraro et al. (2016). NTS1 partial agonists and biased agonists are being explored to separate antipsychotic effects from hypothermia.
Endogenous Antipsychotic-Like Effects
Central neurotensin administration in rodents produces a constellation of effects that closely parallel typical antipsychotic drugs: reduced locomotor activity, blockade of amphetamine- and apomorphine-induced hyperactivity, increased dopamine turnover in the nucleus accumbens, and catalepsy at higher doses Nemeroff et al. (1983). Critically, NT achieves these effects through NTS1 receptor activation rather than dopamine receptor blockade, suggesting a distinct mechanism for modulating psychosis-related dopaminergic hyperactivity. Schizophrenia patients show altered CSF neurotensin levels, and antipsychotic treatment normalizes NT levels, supporting the hypothesis that NT signaling is disrupted in psychotic disorders.
Safety Profile
Neurotensin is an endogenous neuropeptide with well-characterized pharmacological effects. Safety considerations in research and therapeutic development include:
- Hypothermia: The most prominent effect of central NTS1 activation. Dose-dependent reduction in core temperature can be profound (up to 6°C in rodents). This limits NTS1 agonist development but may be therapeutically useful in controlled neuroprotection settings.
- Hypotension: Peripheral NT administration causes dose-dependent vasodilation and hypotension through histamine release and direct vascular effects.
- GI effects: NT stimulates intestinal motility and secretion. High doses may cause diarrhea.
- Catalepsy: At high central doses, NT produces catalepsy-like immobility, analogous to high-dose antipsychotic administration.
- Metabolic effects: Chronic NT signaling promotes fat absorption and storage. Elevated pro-NT is epidemiologically associated with metabolic syndrome and cardiovascular risk.
- No human therapeutic trials: NT receptor agonists for schizophrenia remain preclinical. Toxicology data derive from animal models.
- Rapid degradation: Native NT has a plasma half-life of 2–5 minutes, limiting the duration of any adverse effects from exogenous administration.
Pharmacokinetic Profile
Neurotensin (NT) — Pharmacokinetic Curve
Molecular Structure
- Formula
- C₇₈H₁₂₁N₂₁O₂₀
- Weight
- 1672.9 Da
- CAS
- 39379-15-2
- PubChem CID
- 25077434
- Exact Mass
- 1386.5874 Da
- LogP
- -6.9
- TPSA
- 604 Ų
- H-Bond Donors
- 21
- H-Bond Acceptors
- 24
- Rotatable Bonds
- 41
- Complexity
- 2780
Identifiers (SMILES, InChI)
InChI=1S/C59H86N16O21S/c1-4-29(2)48(74-52(89)37(21-31-9-13-33(77)14-10-31)68-43(79)25-65-55(92)42-8-6-20-75(42)57(94)35(60)17-18-46(82)83)56(93)66-26-45(81)70-40(27-76)53(90)71-36(7-5-19-63-59(61)62)50(87)73-41(28-97)54(91)72-38(23-47(84)85)51(88)67-30(3)49(86)64-24-44(80)69-39(58(95)96)22-32-11-15-34(78)16-12-32/h9-16,29-30,35-42,48,76-78,97H,4-8,17-28,60H2,1-3H3,(H,64,86)(H,65,92)(H,66,93)(H,67,88)(H,68,79)(H,69,80)(H,70,81)(H,71,90)(H,72,91)(H,73,87)(H,74,89)(H,82,83)(H,84,85)(H,95,96)(H4,61,62,63)/t29-,30-,35-,36-,37-,38-,39-,40-,41-,42-,48-/m0/s1
MNVNJFFSXYMCIU-MYVRIFHPSA-NResearch Indications
Neurological
Produces profound naloxone-insensitive analgesia via NTS1 and NTS2 receptors in spinal cord, PAG, and RVM. Effective in acute, neuropathic, and cancer pain models (PMID: 25345606, 16148226).
Brain-penetrant conjugate ANG2002 reversed pain behaviors in neuropathic and bone cancer pain models at 0.05 mg/kg. Preclinical evidence for chronic pain management (PMID: 24531547).
Neurotensin modulates dopaminergic transmission and has been implicated in schizophrenia pathophysiology. NT agonists studied as potential antipsychotic agents. Preclinical evidence.
Metabolic
Peripheral neurotensin involved in glucose homeostasis and feeding behavior regulation via gut-brain axis. Preclinical and early clinical evidence (PMID: 23230428).
Induces hypothermic responses after central administration. Metabolically stable analogs achieved analgesia without hypothermia side effect (PMID: 33607165).
Interactions
Peptide Interactions
Neurotensin produces potent antinociception through a mechanism independent of the opioid system — naloxone does not block NT-induced analgesia. Opioid-neurotensin hybrid peptides (e.g., PK20) demonstrate synergistic antinociceptive potency, with the opioid antagonist naltrexone unable to fully reverse the effect. The chimeric compound KGOP01-NT(8-13) produced prolonged analgesia up to 8 hours: MOR-mediated early, synergistic MOR-NT mid-phase, and NT-mediated late phase (Kleczkowska et al., 2010; Guillemyn et al., 2019).
Neurotensin and Substance P are both found in the enteric nervous system and central pain circuits. While SP is pro-nociceptive via NK1 receptors, NT provides analgesic effects via NTS1/NTS2 receptors through opioid-independent mechanisms. They represent opposing pain modulatory systems. No adverse interactions; they are co-localized in some GI neurons with complementary regulatory functions.
Both neurotensin and somatostatin are found in enteric neurons with evidence of coexistence in some neuronal populations. Somatostatin inhibits neurotensin release in the gut. Both modulate GI secretion and motility through distinct G-protein coupled receptor systems. No antagonistic pharmacological interactions reported.
Neurotensin and VIP are co-localized in specific populations of enteric neurons. VIP is an inhibitory neurotransmitter promoting vasodilation and secretion, while neurotensin has mixed effects on GI motility. Both modulate immune function — VIP is anti-inflammatory via VPAC receptors, neurotensin modulates mast cell activation. No documented adverse interactions; they serve complementary neuroendocrine functions.
Neurotensin modulates the HPA axis by stimulating ACTH release from pituitary corticotrophs. Central administration of neurotensin increases plasma ACTH and corticosterone levels. Combined use may amplify HPA axis activation and cortisol production. Monitor for signs of excessive cortisol response when using neurotensin-based therapies in patients receiving ACTH.
What to Expect
What to Expect
Rapid onset expected; half-life of ~2–5 minutes (plasma) indicates fast-acting pharmacokinetics
Due to short half-life (~2–5 minutes (plasma)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (11)
- [9]Normandeau CP et al — Neurotensin and dopamine interactions in reward and psychiatric disorders: implications for novel therapeutics Neuropsychopharmacology (2023)
- [10]Ferraro L et al — NTS1 receptor agonists as next-generation antipsychotics: progress and challenges Pharmacol Ther (2023)
- [1]Carraway R, Leeman SE The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami J Biol Chem (1973)
- [2]Nemeroff CB, Luttinger D, Hernandez DE, et al Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies J Pharmacol Exp Ther (1983)
- [3]
- [4]Binder EB, Kinkead B, Owens MJ, Nemeroff CB Neurotensin and dopamine interactions Pharmacol Rev (2001)
- [6]Melander O, Maisel AS, Engstrom G, et al Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality JAMA (2012)
- [8]Bhagwandin A et al — Neurotensin-mediated hypothermia as a neuroprotective strategy: translational potential for stroke and TBI Front Neurosci (2022)
- [5]Sarret P, Perron A, Stroh T, Bhattacharyya S Neurotensin analogs with reduced NTS2 activity retain antinociceptive properties J Med Chem (2003)
- [7]Ferraro L, Tomasini MC, Beggiato S, et al Emerging targets in neuropsychopharmacology: the neurotensinergic system Curr Med Chem (2016)
- [11]Li J et al — Pro-neurotensin as a biomarker for metabolic disease and cancer risk: systematic review and meta-analysis BMC Med (2022)
Neuropeptide Y (NPY)
Neuropeptide Y (NPY) is a 36-amino acid peptide and the most abundant neuropeptide in the mammalian brain, playing critical roles in appetite regulation, anxiety modulation, stress resilience, cardiovascular control, and bone metabolism through Y1–Y5 receptor subtypes.
NGF (Nerve Growth Factor)
Nerve Growth Factor (NGF) is a neurotrophic protein essential for the survival, maintenance, and differentiation of sympathetic and sensory neurons. It signals through TrkA and p75NTR receptors and is a major research target in Alzheimer's disease, chronic pain, and corneal nerve regeneration.